Application of Desferal to Treat COVID-19

Kermanshah University of Medical Sciences

Status and phase: Unknown; Phase 2; Phase 1

Conditions: COVID-19

Treatments: Drug: Deferoxamine

Study type: Interventional

Funder types: Other

Identifiers

NCT04333550

1398.1224

Details and patient eligibility

About

In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.

Enrollment: 50 estimated patients

Sex: All

Ages: 3 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of COVID-19 Disease,

Exclusion criteria

Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups

Experimental: Desferal addition to standard treatment

Experimental group

Treatment:

Drug: Deferoxamine

Experimental: standard treatment

Experimental group

Treatment:

Drug: Deferoxamine